Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

CONCLUSION: Eribulin treatment preserved quality of life and geriatric parameters included in the CGA, except for instrumental functioning and geriatric depression, in elderly patients with MBC.
IMPLICATIONS FOR PRACTICE: A collaboration between oncologist and geriatric specialists is essential in the management of patients with metastatic breast cancer, who are frequently elderly or frail. The assessment of geriatric parameters in the decision-making process can contribute to direct toward the most appropriate therapeutic plan and preserve the quality of life of patients. Eribulin does not seem to affect quality of life or worsen the overall geriatric status; therefore, it can be considered a suitable option for elderly patients with metastatic breast cancer.
PMID: 30413667 [PubMed - as supplied by publisher]

Source: The Oncologist - November 9, 2018 Category: Cancer & Oncology Authors: Leo S, Arnoldi E, Repetto L, Coccorullo Z, Cinieri S, Fedele M, Cazzaniga M, Lorusso V, Latorre A, Campanella G, Ciccarese M, Accettura C, Pisconti S, Rinaldi A, Brunetti C, Raffaele M, Coltelli L, Spazzapan S, Fratino L, Petrucelli L, Biganzoli L Tags: Oncologist Source Type: research